Milan, Italy – Exom Group, the Human & Digital CRO, announced and welcomed Luca Visani, MD, as new Chief Medical Officer Oncology (CMOO).
Luca Visani, MD, who is a Radiation Oncology specialist, brings sound experience in Clinical Trials in Oncology, and will be responsible for medical guidance on clinical development of oncology drugs from Phase I to Phase IV studies, as well as the preparation of study protocols, expert opinions, document revisions, trainings and presentation materials, among other tasks. In 2014 Luca received his degree in medicine and surgery cum laude from the University of Florence (Italy), he then further pursued his medical career by specializing in Radiation Oncology at the University of Florence.
During his career professional career, Luca Visani could gain extensive experience as General Practitioner (GP), as well as working on a research project at Radiation Oncology Department, Erasmus MC, Rotterdam, THE Netherlands. He is currently working at the Radiation Oncology Institute of the Medical School of the University of Florence (Azienda Ospedaliero Universitaria Careggi) in Florence, Italy. He has been the author of dozen of publications on the most relevant scientific journals as well as speaker at some congresses and meetings.
Dr. Luigi Visani, CEO and Founder of Exom Group, said that “bringing Luca to our team is further strengthening our solid experience and expertise in the area of oncological clinical trials. Hiring Luca benefits the steady growth of Exom as a leading expert international CRO in digital clinical trials.”
Among the new responsibilities Luca Visani is taking over is the competent and comprehensive consulting of our clients, starting from the study design up to the final report, as well as taking care of the overall subject safety, by taking over the task of medical monitoring.
“We are very much looking forward to working with Luca,” Dr. Visani concluded, “and heartily welcome him as part of our Exom family.”